How would you approach a patient who responded to CDK4/6 inhibitor/endocrine therapy combination for metastatic HR+,HER2- breast cancer who now has disease progression which is biopsy proven TNBC?

Progression was observed only in the breast and required palliative mastectomy (T4b TNBC)

Answer from: Medical Oncologist at Academic Institution

If she has no other distant sites of progression through the cdk4/6, then I would continue this post mastectomy. I would only switch if you have new growing distant mets.

Comments

Medical Oncologist at NYU Winthrop Hospital
I respectfully disagree. If there are no metastas...

Medical Oncologist at Onc San Antonio
Thanks The scenario is: ER positive HER 2 negati...

Medical Oncologist at Newport Breast Care
You mention "one of the masses" progressing in the...

Medical Oncologist at Onc San Antonio
Denovo mets dz. Breast mass, ALN and lung bx - all...

Medical Oncologist at H Lee Moffitt Cancer Center, University of South Florida
Since she is already metastatic, your treatment is...

Medical Oncologist at Warren Alpert Medical School of Brown University
Now that we have these additional details, I agree...

Medical Oncologist at Onc San Antonio
Thank you everyone for your valuable input.

Please select the option that best describes you:

How would you approach a patient who responded to CDK4/6 inhibitor/endocrine therapy combination for metastatic HR+,HER2- breast cancer who now has disease progression which is biopsy proven TNBC?

Related Questions